Hereditas (Mar 2023)

Development and validation of an RBP gene signature for prognosis prediction in colorectal cancer based on WGCNA

  • Lu Cao,
  • Lili Duan,
  • Rui Zhang,
  • Wanli Yang,
  • Ning Yang,
  • Wenzhe Huang,
  • Xuemin Chen,
  • Nan Wang,
  • Liaoran Niu,
  • Wei Zhou,
  • Junfeng Chen,
  • Yiding Li,
  • Yujie Zhang,
  • Jinqiang Liu,
  • Daiming Fan,
  • Hong Liu

DOI
https://doi.org/10.1186/s41065-023-00274-z
Journal volume & issue
Vol. 160, no. 1
pp. 1 – 19

Abstract

Read online

Abstract Background RNA binding proteins (RBPs) have been implicated in oncogenesis and progression in various cancers. However, the potential value of RBPs as prognostic indicators and therapeutic targets in colorectal cancer (CRC) requires further investigation. Methods Four thousand eighty two RBPs were collected from literature. The weighted gene co-expression network analysis (WGCNA) was performed to identify prognosis-related RBP gene modules based on the data attained from the TCGA cohorts. LASSO algorithm was conducted to establish a prognostic risk model, and the validity of the proposed model was confirmed by an independent GEO dataset. Functional enrichment analysis was performed to reveal the potential biological functions and pathways of the signature and to estimate tumor immune infiltration. Potential therapeutic compounds were inferred utilizing CMap database. Expressions of hub genes were further verified through the Human Protein Atlas (HPA) database and RT-qPCR. Results One thousand seven hundred thirty four RBPs were differently expressed in CRC samples and 4 gene modules remarkably linked to the prognosis were identified, based on which a 12-gene signature was established for prognosis prediction. Multivariate Cox analysis suggested this signature was an independent predicting factor of overall survival (P < 0.001; HR:3.682; CI:2.377–5.705) and ROC curves indicated it has an effective predictive performance (1-year AUC: 0.653; 3-year AUC:0.673; 5-year AUC: 0.777). GSEA indicated that high risk score was correlated with several cancer-related pathways, including cytokine-cytokine receptor cross talk, ECM receptor cross talk, HEDGEHOG signaling cascade and JAK/STAT signaling cascade. ssGSEA analysis exhibited a significant correlation between immune status and the risk signature. Noscapine and clofazimine were screened as potential drugs for CRC patients with high-risk scores. TDRD5 and GPC1 were identified as hub genes and their expression were validated in 15 pairs of surgically resected CRC tissues. Conclusion Our research provides a depth insight of RBPs’ role in CRC and the proposed signature are helpful to the personalized treatment and prognostic judgement.

Keywords